Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957136 | 1.00 | CA1 (0.35) | CA1CA2CA4CA5ACA5B | |
| SCHEMBL2631500 | 0.82 | CA1 (0.37) | CA1CA2CA4CA5ACA5B | |
| SCHEMBL19421038 | 0.78 | CA1 (0.35) | CA1CA2CA4CA5ACA5B | |
| SCHEMBL22966529 | 0.78 | CA1 (0.39) | CA1CA2CA4CA5ACA5B | |
| SCHEMBL22545528 | 0.75 | CA1 (0.33) | CA1CA2CA4CA5ACA5B | |
| SCHEMBL19443063 | 0.70 | POLB (0.30) | — | |
| SCHEMBL19236818 | 0.69 | — | — | |
| SCHEMBL18827334 | 0.68 | KMT2A (0.50) | KDM4EHTTKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL23916573 | 0.65 | SMN1; SMN2 (0.32) | CYP1A2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL22065258 | 0.65 | KDM4E (0.41) | KDM4EMEN1CYP1A2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339570-A1 | BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339570-A1 | BICYCLIC DERIVATIVES | CCNY, BICRA, UQCRB | CA1 3286/4885CA2 3963/4885CA4 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.